4hw.com.cn: Recently, China has made a new breakthrough in the field of drugs. The first new anti AIDS drug independently developed in China, ibovetai long-term injection, has been approved by the State Drug Administration for listing. The drug is the world's first long-term anti AIDS fusion inhibitor, with global original intellectual property rights.
AIDS is a major infectious disease in the field of public health. "For a long time, China's AIDS treatment drugs are all imported, there is no independent research and development of new anti AIDS drugs, but the clinical demand for new anti AIDS drugs is growing. "Said Wang Tao, chief reviewer of drug review center and director of Clinical Department II of chemical drugs.
In December 2017, the former State Food and Drug Administration issued and implemented the opinions on encouraging drug innovation to implement priority review and approval, pointing out that the application for registration of drugs against AIDS can be included in the scope of priority review and approval, promoting the review and approval of ibovetai. "The approval of ibovetai means that there are new members of the anti AI medicine. This is also one of the fruitful results after the implementation of the policy of priority review of AIDS treatment drugs. "Said the person in charge of the drug review center.